A Phase I Study of SHR -2001 in Healthy Subjects
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-2001 After a Single or Multiple Subcutaneous Injections in Healthy Subjects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Ye Xu
- Phone Number: 0518-82342973
- Email: ye.xu.yx1@hengrui.com
Study Contact Backup
- Name: Luyao Dong
- Phone Number: 0518-82342973
- Email: luyao.dong@hengrui.com
Study Locations
-
-
Shandong
-
Qingdao, Shandong, China, 266000
- The Affiliated Hospital of Qingdao University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Obtain informed consent from participants before the start of any study related activities. Participants must have a full understanding of the purpose and significance of the trial, and be willing to comply with the trial protocol;
- Age 18 ~ 55 years old (including boundary value), male or female;
- Weight ≥ 45 kg, body mass index (BMI) ranging 19 ~ 28 kg/m2 (including boundary value);
- Participants who are overtly healthy as determined by medical history and physical examination.;
- Participants and their partners have no fertility plan and voluntarily use highly effective contraception. Female subjects must have a negative serum pregnancy test and be non-lactating.
Exclusion Criteria:
- Those who have serious systemic diseases within 3 months before screening or administration, and the investigator believes that there may be safety risks;
- Those who have serious infection, severe trauma or major surgery within 6 months before screening or administration; those who plan to undergo surgery during the trial;
- Inactivated vaccine received within 2 weeks prior to randomization or live attenuated vaccine within 3 months prior to randomization, or intended to be vaccinated during the study period;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Cohort 1
A single subcutaneous injection of SHR-2001/placebo dose 1 in healthy subjects.
|
Subcutaneous injection, single dose or multiple doses.
Subcutaneous injection, single dose or multiple doses.
|
|
Experimental: Cohort 2
A single subcutaneous injection of SHR-2001/placebo dose 2 in healthy subjects.
|
Subcutaneous injection, single dose or multiple doses.
Subcutaneous injection, single dose or multiple doses.
|
|
Experimental: Cohort 3
A single subcutaneous injection of SHR-2001/placebo dose 3 in healthy subjects.
|
Subcutaneous injection, single dose or multiple doses.
Subcutaneous injection, single dose or multiple doses.
|
|
Experimental: Cohort 4
A single subcutaneous injection of SHR-2001/placebo dose 4 in healthy subjects.
|
Subcutaneous injection, single dose or multiple doses.
Subcutaneous injection, single dose or multiple doses.
|
|
Experimental: Cohort 5
A single subcutaneous injection of SHR-2001/placebo dose 5 in healthy subjects.
|
Subcutaneous injection, single dose or multiple doses.
Subcutaneous injection, single dose or multiple doses.
|
|
Experimental: Cohort 6
A single subcutaneous injection of SHR-2001/placebo dose 6 in healthy subjects.
|
Subcutaneous injection, single dose or multiple doses.
Subcutaneous injection, single dose or multiple doses.
|
|
Experimental: Cohort 7
A single subcutaneous injection of SHR-2001/placebo dose 7 in healthy subjects.
|
Subcutaneous injection, single dose or multiple doses.
Subcutaneous injection, single dose or multiple doses.
|
|
Experimental: Cohort 8
A single subcutaneous injection of SHR-2001 / placebo dose 8 in healthy subjects.
|
Subcutaneous injection, single dose or multiple doses.
Subcutaneous injection, single dose or multiple doses.
|
|
Experimental: Cohort 9
A single subcutaneous injection of SHR-2001 / placebo dose 9 in healthy subjects.
|
Subcutaneous injection, single dose or multiple doses.
Subcutaneous injection, single dose or multiple doses.
|
|
Experimental: Cohort 10
A single subcutaneous injection of SHR-2001 / placebo dose 10 in healthy subjects.
|
Subcutaneous injection, single dose or multiple doses.
Subcutaneous injection, single dose or multiple doses.
|
|
Experimental: Cohort 11
A multiple subcutaneous injection of SHR-2001 / placebo dose 11 in healthy subjects.
|
Subcutaneous injection, single dose or multiple doses.
Subcutaneous injection, single dose or multiple doses.
|
|
Experimental: Cohort 12
A multiple subcutaneous injection of SHR-2001 / placebo dose 12 in healthy subjects.
|
Subcutaneous injection, single dose or multiple doses.
Subcutaneous injection, single dose or multiple doses.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adverse events
Time Frame: Start of Treatment to end of study (approximately 64 days).
|
Incidence and severity of adverse events
|
Start of Treatment to end of study (approximately 64 days).
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pharmacokinetics-AUC0-t
Time Frame: Start of Treatment to end of study (approximately 64 days).
|
Area under the concentration-time curve from 0 to the last measurable time point after SHR-2001 administration
|
Start of Treatment to end of study (approximately 64 days).
|
|
Pharmacokinetics-AUC0-inf
Time Frame: Start of Treatment to end of study (approximately 64 days).
|
Area under the concentration-time curve from time 0 to infinity after SHR-2001 administration
|
Start of Treatment to end of study (approximately 64 days).
|
|
Pharmacokinetics-Cmax
Time Frame: Start of Treatment to end of study (approximately 64 days).
|
Maximum observed concentration of SHR-2001
|
Start of Treatment to end of study (approximately 64 days).
|
|
Pharmacokinetics-Tmax
Time Frame: Start of Treatment to end of study (approximately 64 days).
|
Time to Cmax
|
Start of Treatment to end of study (approximately 64 days).
|
|
Pharmacokinetics-t1/2
Time Frame: Start of Treatment to end of study (approximately 64 days).
|
Terminal elimination half-life of SHR-2001
|
Start of Treatment to end of study (approximately 64 days).
|
|
Pharmacokinetics-CL/F
Time Frame: Start of Treatment to end of study (approximately 64 days).
|
Apparent clearance of SHR-2001
|
Start of Treatment to end of study (approximately 64 days).
|
|
Pharmacokinetics-Vz/F
Time Frame: Start of Treatment to end of study (approximately 64 days).
|
Apparent volume of distribution during terminal phase of SHR-2001
|
Start of Treatment to end of study (approximately 64 days).
|
|
Anti-Drug antibody
Time Frame: Start of Treatment to end of study (approximately 64 days).
|
The percentage of subjects with positive ADA
|
Start of Treatment to end of study (approximately 64 days).
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- SHR-2001-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.